YF476 and Type II Gastric Carcinoids

Summary

This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Timeline

Start

2011-04-11

Primary completion

2012-06-22

Completion

2012-06-22

Outcome

Outcome not reported

Stopped (Enrollment): “Poor recruitment”

Drugs

Indications